Cyteir Therapeutics Inc. (CYT)
3.02
-0.07 (-2.27%)
At close: Mar 15, 2024, 8:00 PM
Company Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines.
Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies.
The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies.
The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Cyteir Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Dr. Markus F. Renschler M.D. |
Contact Details
Address: 128 Spring Street Lexington, Massachusetts United States | |
| Website | https://cyteir.com |
Stock Details
| Ticker Symbol | CYT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001662244 |
| CUSIP Number | 550241103 |
| ISIN Number | US23284P1030 |
| Employer ID | 45-5429901 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Markus F. Renschler M.D. | President, Chief Executive Officer & Director |
| David G. Gaiero | Chief Financial Officer & Treasurer |
| Dr. Kevin Mills Ph.D. | Co-Founder |
| Joseph S. Zakrzewski | Independent Investor & Independent Chairman of the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 29, 2024 | 15-12G | Filing |
| Mar 25, 2024 | 4 | Filing |
| Mar 21, 2024 | S-8 POS | Filing |
| Mar 21, 2024 | S-8 POS | Filing |
| Mar 21, 2024 | S-8 POS | Filing |
| Mar 21, 2024 | AW | Filing |
| Mar 21, 2024 | AW | Filing |
| Mar 21, 2024 | AW | Filing |
| Mar 20, 2024 | 8-K | Current Report |
| Mar 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |